Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2020 Jun;35(6):1009-1013.
doi: 10.1002/jbmr.4049. Epub 2020 May 26.

Osteoporosis Management in the Era of COVID-19

Elaine W Yu  1 , Elena Tsourdi  2   3 , Bart L Clarke  4 , Douglas C Bauer  5   6 , Matthew T Drake  4   7
Affiliations
Practice Guideline

Osteoporosis Management in the Era of COVID-19

Elaine W Yu et al. J Bone Miner Res. 2020 Jun.

Abstract

Osteoporosis is a chronic condition that reflects reduced bone strength and an associated increased risk for fracture. As a chronic condition, osteoporosis generally requires sustained medical intervention(s) to limit the risks for additional bone loss, compromise of skeletal integrity, and fracture occurrence. Further complicating this issue is the fact that the abrupt cessation of some therapies can be associated with an increased risk for harm. It is in this context that the COVID-19 pandemic has brought unprecedented disruption to the provision of health care globally, including near universal requirements for social distancing. In this Perspective, we provide evidence, where available, regarding the general care of patients with osteoporosis in the COVID-19 era and provide clinical recommendations based primarily on expert opinion when data are absent. Particular emphasis is placed on the transition from parenteral osteoporosis therapies. It is hoped that these recommendations can be used to safely guide care for patients with osteoporosis until a return to routine clinical care standards is available. © 2020 American Society for Bone and Mineral Research.

Keywords: ABALOPARATIDE; BISPHOSPHONAT; COVID-19; DENOSUMAB; FRACTURES; OSTEOPOROSIS; ROMOSOZUMAB; TERIPARATIDE.

PubMed Disclaimer

Comment in

References

    1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. - PMC - PubMed
    1. WHO. Coronavirus disease 2019 (COVID‐19): situation report–106. Geneva: World Health Organization; 2020. Available at: https://www.who.int/docs/default-source/coronaviruse/situation-reports/2....
    1. Rosenbaum L. The untold toll—the pandemic's effect on patients without Covid‐19. N Engl J Med. Epub 2020. Apr 7. DOI: 10.1056/NEJMms2009984. - DOI - PubMed
    1. Ray NF, Chan JK, Thamer M, Melton LJ 3rd. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res. 1997;12(1):24–35. - PubMed
    1. ASBMR. ASBMR webinar panel on treating patients with osteoporosis during the COVID‐19 pandemic. Washington, DC: ASBMR; 2020. Available at: https://www.asbmr.org/education‐detail?cid=b92753f3‐0a28‐4f37‐9a58‐6ded5....

MeSH terms